Heron Therapeutics, Inc. (HRTX) vs Xilio Therapeutics, Inc. (XLO)
A side-by-side comparison of Heron Therapeutics, Inc. and Xilio Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
HRTX
Heron Therapeutics, Inc.
$0.33HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
XLO
Xilio Therapeutics, Inc.
$9.00HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — HRTX vs XLO
growth of $100 · dividends reinvested · last 5yHRTX -96.5% (-48.8%/yr)XLO -95.9% (-47.3%/yr)XLO compounded faster over this window
HRTX XLO
HRTX vs XLO: by the numbers
- •HRTX is the larger company ($63M vs $59M market cap).
- •Both run net losses; HRTX's is the smaller (-22.52% vs -34.06% net margin).
Metrics side by side
Valuation
| Metric | HRTX | XLO |
|---|---|---|
| P/S ratio | 0.42 | 0.92 |
| P/B ratio | 10.72 | 0.82 |
Profitability
| Metric | HRTX | XLO |
|---|---|---|
| Gross margin | 70.07% | 99.46% |
| Operating margin | -7.19% | -95.92% |
| Net margin | -22.52% | -34.06% |
| ROE | -492.89% | -30.21% |
| ROIC | -6.79% | -26.13% |
Growth (annualized)
| Metric | HRTX | XLO |
|---|---|---|
| Revenue CAGR (5Y) | 12.73% | N/A |
| Total return CAGR (5Y) | -48.61% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.